Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder

Next Previous
Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Darigabat (Primary)
  • Indications Panic disorder
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ADAPT
  • Sponsors AbbVie; Cerevel Therapeutics

Most Recent Events

  • 04 Apr 2025 Status changed from recruiting to completed.
  • 01 Aug 2024 According to an AbbVie media release, AbbVie has acquired Cerevel Therapeutics.
  • 02 Apr 2024 Planned number of patients changed from 228 to 246.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top